First, Do No Harm:

The Role of Cannabis Education in Response to the Opioid Crisis

Abstract

Recent years have seen unprecedented levels of accidental overdose deaths in British Columbia. In response, the College of Physicians and Surgeons released guidelines to reduce over-prescribing. Unfortunately, many Canadians continue to suffer with chronic pain and offering suitable treatment alternatives is a priority. Since 1999 the courts have recognized patient’s rights to use cannabis for therapeutic purposes (CTP) and the government recently tasked physicians as gatekeepers to CTP. However, there is need for greater educational opportunities related to CTP for clinicians engaged in pain management in order to ensure that lack of knowledge is not a barrier to accessing a potentially effective therapy with a safety profile that is superior to opioids.

Chronic pain (CP) is a scourge to Canadians with one in five living with the debilitating condition (1); it is associated with an increased risk of comorbid psychological illnesses (2), significantly lowers quality of life, and increased mortality (3). Additionally, the costs incurred from CP are staggering; in 2010 it was estimated that CP cost the Canadian healthcare system more than $6 billion dollars annually and productivity costs related to job loss and sick days were estimated at $37 billion (4).

In the 1990s, opioids emerged as a primary treatment for CP. Due in part to increased marketing efforts by pharmaceutical companies of novel opioid analgesics (i.e., OxyContin) that purportedly improved the “efficiency and quality of pain management…without unacceptable side-effects” (5). These campaigns contributed to significant increases in the prescription of opioids; oxycodone prescriptions increased by 850% between 1991 and 2007 (6). OxyContin was pulled from the market in 2012 and a subsequent influx of illicit opioids began to fill the void that had been created (5). In April 2016 Dr. Perry Kendall, British Columbia’s Provincial Medical Health Officer, declared a public health emergency in response to the increasing number of overdoses occurring in British Columbia. A majority of these overdoses were the direct result of opioids (7).

Although they are widely prescribed for pain relief (8), opioid therapies are controversial as they pose a risk for dependence and potential for fatal overdose due to tolerance and drug-interaction. Despite the risks, opioids continue to be prescribed to Canadians at a high rate. In 2015, physicians wrote 53 opioid prescriptions for every 100 people in Canada (9). As such, Canada ranks second in the rate of opioid prescription of all developed countries (10). In British Columbia, prescription of strong opioids saw an increase of 50% from 2005 to 2011 (11) and in 2016 the College of Physicians and Surgeons of British Columbia released standards and guidelines in an attempt to reduce over-prescribing of opioids. The standards state that non-pharmacologic and non-opioid analgesics (e.g., nonsteroidal anti-inflammatory drugs) are preferred for the treatment of chronic non-cancer pain and that the potential benefit of long-term opioid treatment is modest with significant risks. Nevertheless, opioids still play an important role in pain management in certain patient populations. For example, the Fraser Health Authority recommends opioids in patients with advanced illnesses and in patients with cancer and non-cancer debilitating pain that is refractory to non-opioid medications (12).

For some patients cannabis may be a suitable alternative to opioid analgesics. Cannabis is a complex therapeutic agent that possesses psychoactive, analgesic, and anxiolytic capabilities and it has been posited that cannabis not only modulates pain signaling but may also improve psychological aspects implicated in pain perception, such as mood and sleep (13,14). In contrast to opioid analgesics, cannabis has a relatively low risk of dependence and no risk of fatal overdose (15). Many patients report using cannabis effectively to treat their pain (16,17) and 30% of patients report substituting opioid medication with cannabis (17). Findings from a recent review provide evidence of the efficacy of cannabis for pain. Of 38 published randomized clinical trials 71% concluded that cannabinoids had empirically demonstrable and significant pain relieving effects (18).

Since 1999, the Canadian courts have recognized the rights of patients to access CTP under Health Canada’s Medical Marihuana Access Program (19). The government program has gone through several iterations and is now the Access to Cannabis for Medical Purposes Regulations which authorizes physicians to provide medical documentation allowing patients to access CTP from government authorized producers of cannabis (i.e., Licensed Producers). Currently, there are well over 100 000 CTP patients registered in the government program (20) and this number is expected to rise to 400 000 over the next few years (19). The incoming Cannabis Act will likely increase access to CTP as patients who formerly experienced barriers finding a physician to authorize CTP will be able access cannabis outside of the medical system.

However, despite its apparent promise as an analgesic, the College of Family Physicians of Canada (CFPC) guidelines recommend CTP as a last resort in light of a paucity of research on the effectiveness and long-term consequences of using cannabis to treat pain (21). Given the current opioid crisis, the good safety profile of cannabis, and the dozens of studies reporting cannabis as effective for pain relief, this stance seems unduly conservative. Indeed, although physicians are integral to the process of patients acquiring CTP, physicians may perceive themselves as lacking the necessary knowledge about benefits, harms, indications, and appropriate treatment plans pertaining to CTP. Researchers from McGill University recently conducted a national survey aimed at determining the educational needs pertaining to CTP among physicians. They concluded that there was a clear need for education on the use of CTP, dosing, and creating effective treatment plans, and that the inclusion of CTP in physician practices would likely increase with additional education in formats such as online learning programs as part of continuing education and workshops (22). Finally, increased educational opportunities should begin in medical school so that physicians feel comfortable once they are in active practice. Such opportunities have the potential to play an important role in increasing physician comfort with this potentially valuable option for the treatment of CP.

Many questions surrounding CTP still need to be answered but the therapeutic potential of cannabis in the treatment of CP and other conditions is encouraging. As the number of individuals using cannabis for therapeutic and non-medical purposes increases, governing bodies must update their recommendations with emerging research findings. Additionally, greater educational opportunities about CTP should be made available such that patients can receive a greater standard of care and greater treatment options that may ultimately increase access to CTP for patients whom it is a viable option. Cannabis must be subject to the same risk-benefit analysis as other medications and an important aspect of that is appropriate training for the health care professionals tasked with authorizing its use.

Reference List

1. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada – prevalence, treatment, impact and the role of opioid analgesia. *Pain Research Management*.2002;7(4): 179-184.
2. Canadian Psychological Association (CPA). Chronic Pain. 2007. Available from [www.cpa.ca/psychologyfactsheets/chronicpain/](http://www.cpa.ca/psychologyfactsheets/chronicpain/) [Accessed 1st February 2017].
3. Schopflocher D, Taenzer P, Jovey, R. The prevalence of chronic pain in Canada. *Pain Research Management*. 2011;16(6): 445-450.
4. Phillips CJ, Schopflocher D. The economics of chronic pain. *Chronic Pain: A Health Policy Perspective*. 2008. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/9783527622665.ch4/summary> [Accessed on 1st February 2017].
5. Robertson G, Howlett, K. How a little-known patent sparked Canada’s opioid crisis *The Globe and Mail.* 2017. Available from: <http://www.theglobeandmail.com/news/investigations/oxycontin/article33448409/> [Accessed 8 May 2017].
6. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink, DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. *Canadian Medical Association Journal*. 2009;181(12): 891-896.
7. B.C.’s Opioid Overdose Response: Progress Update. *B.C.’s Public Health Emergency Progress Update on B.C.’s Response to the Opioid Overdose Crisis*. 2016. Available from: <http://www2.gov.bc.ca/assets/gov/health/about-bc-s-health-care-system/office-of-the-provincial-health-officer/overdose-response-progress-update-sept2016.pdf> [Accessed on 1st February 2017].
8. Portenoy RK, Payne R, Passik SK, Lowinson JH, Ruz P, Millman RB, Langrod JG. (2004). Acute and Chronic Pain*.* In Lippincott, Williams, & Wilken (Eds.), *Substance Abuse: A Comprehensive Textbook. 4th ed.* (pp. 863–904). Philadelphia: USA.
9. Howlett K. Canada’s expensive habit: Adding up opioid abuse’s rising financial toll on the health-care system. *The Globe and Mail*. 2017. Available from: <http://www.theglobeandmail.com/news/investigations/opioids/article31464607/> [Accessed 1st February 2017].
10. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. *Pain Physician*. 2012;15:ES191-203.
11. College of Physicians and Surgeons of British Columbia. *Safe Prescribing of Drugs with Potential for Misuse/Diversion.* Professional Standards and Guidelines.2016. Available from: <https://www.cpsbc.ca/files/pdf/PSG-Safe-Prescribing.pdf> [Accessed 1st February 2017].
12. Fraser Health. *Principles of Opioid Management.* 2006. Available from <https://www.fraserhealth.ca/media/16FHSymptomGuidelinesOpioid.pdf> [Accessed 8 May 2017].
13. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji S-P, Bai G, Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects. *Journal of Clinical Investigation*. 2014;115(11): 3104-3116.
14. Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: A systematic review of human studies. *Sleep Medicine Reviews*. 2014;18: 477 – 487.
15. Ware MA, Wang T, Shapiro S, Collet J-P. Cannabis for the management of pain: assessment of safety study (COMPASS). *Journal of Pain*. 2015;16(12): 1233-1242.
16. Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, Holtzman S. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. *International Journal of Drug Policy*.2013;24: 511-516.
17. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. *International Journal of Drug Policy*. 2017;42:30-35.
18. Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. *Clinical Journal of Pain.* 2013;29(2): 162-171. doi:10.1097/AJP.0b013e31824c5e4c
19. Marihuana for Medical Purposes Regulations: Regulatory impact analysis statement. Canada Gazette; 2012. Available from:<http://gazette.gc.ca/rp-pr/p1/2012/2012-12-15/html/reg4-eng.html> [Accessed 1st February 2017].
20. Health Canada (2016). *Drug and Health Products.* Available from<http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/market-marche-eng.php> [Accessed 1st February 2017].
21. College of Family Physicians of Canada. *Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance from the College of Family Physicians of Canada.* Mississauga, ON: College of Family Physicians of Canada; 2014.
22. Ziemianski D, Capler R., Tekanoff R, Lacasse A, Luconi F, Ware M. Cannabis in medicine: A national educational needs assessment among Canadian physicians. *BMC Medical Education.* 2015;15: 52.